Blue Earth Appoints New CEO and CMO

By News Release

Blue Earth Diagnostics announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO) and the promotion of Eugene J. Teoh, MBBS, MRCP, FRCR, D.Phil., to Chief Medical Officer (CMO). The changes reflect a new phase of growth and global corporate development for Blue Earth Diagnostics.

Former CEO and Executive Chairman Jonathan Allis, D.Phil., assumes the role of Honorary Chairman of the Blue Earth Diagnostics Board of Directors. Dr. Gauden will retain his current responsibilities as President, Research and Development and Chief Scientific Officer and report to Bracco Imaging CEO Fulvio Renoldi Bracco. Terri Wilson, President of BED Inc. (US), will assume additional responsibilities in support of Blue Earth Diagnostics, including global commercial responsibilities.

Dr. Gauden, a co-founder of Blue Earth Diagnostics, brings more than 20 years of industry expertise in radiopharmaceuticals and diagnostic medical imaging to his new role. Prior to the founding of Blue Earth Diagnostics in 2014, Dr. Gauden served as Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the product portfolio, licensing, product development and strategic marketing activities across a range of developmental PET drugs. Dr. Gauden holds an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.

“Blue Earth Diagnostics is poised to achieve significant near-term milestones in our mission to deliver diagnostic imaging solutions to inform and guide the clinical management of patients with cancer,” said Dr. Gauden. “I am excited and honored to assume the role of CEO as our Company enters a new stage of growth. As the recognized leader in PET prostate cancer diagnostic imaging, we are actively progressing our comprehensive prostate cancer portfolio, which includes 18F-fluciclovine and our investigational rhPSMA technology platform. Our investigational program for the use of 18F-fluciclovine in neuro-oncology and other applications is well underway, as are plans to acquire additional diagnostic imaging technology. Speaking on behalf of the entire Company, we want to express our sincere thanks to our founding CEO, Jonathan Allis, who, in his eight years of unswerving commitment and deep, strategic insight, advanced Blue Earth to the industry leadership position that it holds today.”

Dr. Teoh, Blue Earth Diagnostics’ new CMO, reports to CEO David Gauden. He joined the Company in 2018 as European (EU) Medical Director and was subsequently promoted to Vice President Clinical Development. He takes the reins from former CMO Peter Gardiner, MB ChB, FRCP, FFPM, who will continue to serve in a strategic advisory capacity through 2022. As CMO, Dr. Teoh has overall medical oversight and will contribute to strategic direction and guide development of innovative molecular imaging products to help guide clinicians in the diagnosis and management of cancer patients. 

“It is an honor to take the role of CMO at Blue Earth Diagnostics, and I am committed to continuing our success in the development of radiopharmaceuticals to fulfil an unmet medical need for clinicians and improve patient care,” said Dr. Teoh. “This is a pivotal time for Blue Earth Diagnostics as a growing international diagnostic imaging company. We look forward to sharing results of our efforts as we work to provide well-differentiated solutions to best inform patient care.”

Back To Top

Blue Earth Appoints New CEO and CMO.  Appl Radiol. 

By News Release| March 02, 2022

About the Author

News Release

News Release

Copyright © Anderson Publishing 2022